Jupiter Neurosciences Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
JUNS
- Investments
-
1
- Share Price
-
$1.24
- (As of Friday Closing)
Jupiter Neurosciences General Information
Description
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Contact Information
Website
www.jupiterneurosciences.comCorporate Office
- 1001 North US Highway 1
- Suite 504
- Palm Beach Gardens, FL 33477
- United States
Corporate Office
- 1001 North US Highway 1
- Suite 504
- Palm Beach Gardens, FL 33477
- United States
Jupiter Neurosciences Stock Performance
As of 20-Nov-2026, Jupiter Neurosciences’s stock price is $1.24. Its current market cap is $1.63M with 1.32M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.24 | $1.46 | $1.20 - $97.74 | $1.63M | 1.32M | 876K | -$22.42 |
Jupiter Neurosciences Financials Summary
As of 30-Sep-2026, Jupiter Neurosciences has a trailing 12-month revenue of $78.6K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,444 | 34,571 | 356,575 | |
| Revenue | 79 | 22 | 0 | 0 |
| EBITDA | (13,798) | (8,579) | (2,197) | (4,565) |
| Net Income | (14,135) | (8,645) | (2,440) | (4,784) |
| Total Assets | 1,623 | 5,564 | 6,202 | 149 |
| Total Debt | 451 | 5,319 | 218 | 2,248 |
Jupiter Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jupiter Neurosciences Comparisons
Industry
Financing
Details
Jupiter Neurosciences Competitors (6)
One of Jupiter Neurosciences’s 6 competitors is Biohaven, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biohaven | Formerly VC-backed | New Haven, CT | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Larimar Therapeutics | Formerly VC-backed | Bala Cynwyd, PA | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| IRulya Therapeutics | Formerly VC-backed | New Haven, CT |
Jupiter Neurosciences Patents
Jupiter Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230075521-A1 | Resveratrol pharmaceutical compositions and methods of use thereof | Inactive | 20-Aug-2021 | ||
| WO-2023023323-A1 | Resveratrol pharmaceutical compositions and methods of use thereof | Inactive | 20-Aug-2021 | ||
| US-10780056-B2 | Resveratrol solubilisation product for pharmaceutical purposes | Active | 14-Jun-2016 | ||
| US-20190307700-A1 | Resveratrol solubilisation product for pharmaceutical purposes | Active | 14-Jun-2016 | A61K9/1075 |
Jupiter Neurosciences Signals
Jupiter Neurosciences Investments (1)
Jupiter Neurosciences’s most recent deal was a Corporate Asset Purchase with PharmAla Biotech (Rights of Drug ALA-002 and Royalty in Toronto, Canada) for . The deal was made on 20-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PharmAla Biotech (Rights of Drug ALA-002 and Royalty in Toronto, Canada) | 20-Jun-2026 | Corporate Asset Purchase | Buildings and Property |
Jupiter Neurosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Jupiter Neurosciences FAQs
-
When was Jupiter Neurosciences founded?
Jupiter Neurosciences was founded in 2015.
-
Where is Jupiter Neurosciences headquartered?
Jupiter Neurosciences is headquartered in Palm Beach Gardens, FL.
-
What is the size of Jupiter Neurosciences?
Jupiter Neurosciences has 8 total employees.
-
What industry is Jupiter Neurosciences in?
Jupiter Neurosciences’s primary industry is Drug Discovery.
-
Is Jupiter Neurosciences a private or public company?
Jupiter Neurosciences is a Public company.
-
What is Jupiter Neurosciences’s stock symbol?
The ticker symbol for Jupiter Neurosciences is JUNS.
-
What is the current stock price of Jupiter Neurosciences?
As of 20-Nov-2026 the stock price of Jupiter Neurosciences is $1.24.
-
What is the current market cap of Jupiter Neurosciences?
The current market capitalization of Jupiter Neurosciences is $1.63M.
-
What is Jupiter Neurosciences’s current revenue?
The trailing twelve month revenue for Jupiter Neurosciences is $78.6K.
-
Who are Jupiter Neurosciences’s competitors?
Biohaven, Denali Therapeutics, Larimar Therapeutics, Biogen, and IRulya Therapeutics are some of the 6 competitors of Jupiter Neurosciences.
-
What is Jupiter Neurosciences’s annual earnings per share (EPS)?
Jupiter Neurosciences’s EPS for 12 months was -$22.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process